@article{riggs_schaefer_kapil_barley-maloney_perryman_2002, title={Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis}, volume={46}, ISSN={["1098-6596"]}, DOI={10.1128/AAC.46.2.275-282.2002}, abstractNote={ABSTRACT Cryptosporidium parvum is an important cause of diarrhea in humans and calves and can persistently infect immunocompromised hosts. Presently, there are no consistently effective parasite-specific drugs for cryptosporidiosis. We hypothesized that neutralizing monoclonal antibodies (MAbs) targeting the apical complex and surface antigens CSL, GP25-200, and P23 could passively immunize against cryptosporidiosis. We recently reported that a formulation of MAbs 3E2 (anti-CSL), 3H2 (anti-GP25-200), and 1E10 (anti-P23) provided significant additive prophylactic efficacy over that of the individual MAbs in neonatal ICR mice. In the present study, these MAbs were evaluated for therapeutic efficacy against persistent infection in adult gamma interferon-depleted SCID mice. 3E2 demonstrated the most significant and consistent therapeutic effect, reducing intestinal infection in two experiments. In one experiment, 3E2 plus 3H2 and 3E2 plus 3H2 plus 1E10 also significantly reduced infection; however, no significant increase in efficacy over 3E2 alone was apparent. The results indicate that anti-CSL MAb 3E2 has highly significant efficacy in reducing, but not eliminating, persistent C. parvum infection.}, number={2}, journal={ANTIMICROBIAL AGENTS AND CHEMOTHERAPY}, author={Riggs, MW and Schaefer, DA and Kapil, SJ and Barley-Maloney, L and Perryman, LE}, year={2002}, month={Feb}, pages={275–282} }
 @article{riggs_schaefer_kapil_barley-maloney_perryman_mcneil_2001, title={Targeted disruption of CSL ligand-host cell receptor interaction in treatment of Cryptosporidium parvum infection}, number={2001}, journal={Journal of Eukaryotic Microbiology}, author={Riggs, M. W. and Schaefer, D. A. and Kapil, S. J. and Barley-Maloney, L. and Perryman, L. E. and McNeil, M. R.}, year={2001}, pages={44S–46} }
 @article{perryman_kapil_jones_hunt_1999, title={Protection of calves against cryptosporidiosis with immune bovine colostrum induced by a Cryptosporidium parvum recombinant protein}, volume={17}, ISSN={["0264-410X"]}, DOI={10.1016/S0264-410X(98)00477-0}, abstractNote={The purpose of the study was to determine if immunization with a recombinant protein (rC7) of Cryptosporidium parvum would induce immune bovine colostrum that protected calves against cryptosporidiosis following oral challenge with C. parvum oocysts. Late gestation Holstein cows with low titers of antibody to the p23 antigen of C. parvum were immunized three times with 300 μg affinity purified rC7 C. parvum recombinant protein (immune cows), or left nonimmunized (control cows). Colostrum was obtained from each cow in both groups and partitioned into identical aliquots of pooled immune colostrum or pooled control colostrum. Twelve calves obtained at birth received either immune or control colostrum within the first 2 h, and again at 12 and 24 h of age. Each calf was challenged orally with 107 C. parvum oocysts at 12 h of age and monitored for signs of cryptosporidiosis. All six calves administered pooled control colostrum developed severe diarrhea (mean total fecal volume=8447±5600 ml) and shed an average of 1.87±1.66×1012 C. parvum oocysts. None of the six calves administered pooled immune colostrum developed diarrhea (mean total fecal volume=740±750 ml, p<0.05), and shed significantly fewer oocysts (3.05±2.26×109, p<0.05). The absence of diarrhea and 2.79 log10 (99.8%) reduction in oocyst excretion indicates that immune bovine colostrum induced by immunization with C. parvum recombinant protein rC7 provided substantial protection against cryptosporidiosis in neonatal calves.}, number={17}, journal={VACCINE}, author={Perryman, LE and Kapil, SJ and Jones, ML and Hunt, EL}, year={1999}, month={Apr}, pages={2142–2149} }